Akebia Therapeutics (FRA:AX9) Shiller PE Ratio: (As of Aug. 30, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:AX9 Akebia Therapeutics Inc FRA:AX9
47 GF Score
Price €0.78
GF Value €1.07
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Akebia Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Akebia Therapeutics  (FRA:AX9) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Akebia Therapeutics Shiller PE Ratio Related Terms


Akebia Therapeutics Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Akebia Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akebia Therapeutics Shiller PE Ratio Chart

Akebia Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Akebia Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:AX9 vs ORGO, EBS, TKNO: Shiller PE Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Akebia Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akebia Therapeutics Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Akebia Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Akebia Therapeutics's Shiller PE Ratio falls into.


FRA:AX9
47GF Score
Akebia Therapeutics Inc FRA:AX9
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Akebia Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Akebia Therapeutics's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, Akebia Therapeutics's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.026/333.9520*333.9520
=-0.026

Current CPI (Jun. 2026) = 333.9520.

Akebia Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 -0.855 241.428 -1.183
201612 -0.939 241.432 -1.299
201703 -1.075 243.801 -1.473
201706 -0.472 244.955 -0.643
201709 -0.411 246.819 -0.556
201712 0.355 246.524 0.481
201803 -0.389 249.554 -0.521
201806 -0.514 251.989 -0.681
201809 -0.394 252.439 -0.521
201812 -0.665 251.233 -0.884
201903 -0.549 254.202 -0.721
201906 -0.434 256.143 -0.566
201909 -0.418 256.759 -0.544
201912 -0.711 256.974 -0.924
202003 -0.425 258.115 -0.550
202006 -1.137 257.797 -1.473
202009 -0.357 260.280 -0.458
202012 -0.493 260.474 -0.632
202103 -0.378 264.877 -0.477
202106 -0.423 271.696 -0.520
202109 -0.289 274.310 -0.352
202112 -0.354 278.802 -0.424
202203 -0.318 287.504 -0.369
202206 0.142 296.311 0.160
202209 -0.293 296.808 -0.330
202212 -0.038 296.797 -0.043
202303 -0.140 301.836 -0.155
202306 -0.055 305.109 -0.060
202309 -0.075 307.789 -0.081
202312 0.003 306.746 0.003
202403 -0.083 312.332 -0.089
202406 -0.037 314.175 -0.039
202409 -0.090 315.301 -0.095
202412 -0.096 315.605 -0.102
202503 0.028 319.799 0.029
202506 0.000 322.561 0.000
202509 0.000 324.800 0.000
202512 -0.043 324.054 -0.044
202603 -0.026 330.213 -0.026
202606 -0.026 333.952 -0.026

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Akebia Therapeutics (FRA:AX9) Overvalued in 2026?

Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be undervalued. The current stock price of €0.78 is trading 27.6% below its estimated GF Value™ of €1.07. GuruFocus considers Akebia Therapeutics to be Modestly Undervalued.

Key valuation signals for FRA:AX9:

  • Shiller PE Ratio:
  • GF Value™: €1.07 vs. price of €0.78 (27.6% below fair value)
  • GF Score™: 47/100 with 4 warning signs

No single metric tells the full story. See the FRA:AX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Akebia Therapeutics Business Description

Other Exchanges AKBA:USAAX9:Germany
Address 245 First Street, Suite 1400, Cambridge, MA, USA, 02142
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
47GF Score

Get the complete analysis for FRA:AX9

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.78
Price
€1.07
GF Value